Three Major Sponsors Converge on Medical Textiles as Regulatory Moats Drive Inelastic Demand

Three major private equity firms have separately staked capital on medical textiles and fertility services, converging on a thesis that healthcare supply chains and demographic demand are colliding to create persistent pricing power in specialized consumables and essential services. Montagu, Kohlberg, and Arlington have each made bets on medical textiles providers, while Amulet Capital Partners is pursuing a continuation vehicle for US Fertility as demand for fertility treatment climbs . The moves signal institutional capital's pivot toward healthcare infrastructure plays that sit upstream of clinical outcomes but downstream of volatile reimbursement models.

Financial details of the medical textiles transactions were not disclosed, nor were purchase price multiples or revenue figures for the target companies . The simultaneous deployment across three sponsors suggests deal processes ran in parallel rather than competitive auctions, reflecting the fragmented nature of the medical textiles supply base. US Fertility's continuation vehicle structure indicates Amulet is extending its hold period to capture additional value creation as patient volumes rise, a tactical shift that mirrors broader GP behavior in 2026 as exit windows remain selective .

The capital allocation represents a bet on inelastic demand: hospitals and surgical centers cannot substitute away from sterile drapes, gowns, and single-use textiles without regulatory violations, and fertility clinics face rising patient demand driven by delayed childbearing and improved insurance coverage. For institutional allocators, these investments offer recession-resistant cash flows tied to procedure volumes rather than discretionary consumer spending.

Convergence on Consumables: Why Three Sponsors Chased the Same Sector

The clustering of Montagu, Kohlberg, and Arlington in medical textiles is not coincidental. It reflects a structural thesis: as healthcare systems globally face labor shortages and capacity constraints, outsourced medical consumables with sticky customer relationships and regulatory moats become scarce assets. Medical textiles sit at the intersection of manufacturing scale and healthcare compliance, a combination that creates natural consolidation platforms.

Our interpretation: the three firms likely pursued different subsectors within medical textiles. Montagu has historically favored European mid-market healthcare services and suppliers, Kohlberg has concentrated on North American manufacturing and distribution roll-ups, and Arlington has deployed across both geographies with a tilt toward products requiring technical certifications. The lack of disclosed financials suggests early-stage platform builds rather than mature carve-outs, positioning each sponsor to execute buy-and-build strategies over 18 to 24 months.

The timing aligns with broader industrial trends. Defense manufacturing capacity is expanding rapidly in the United States, with new entrants like Covenant raising over $250 million to scale missile production in Texas and Germany . While defense and medical textiles occupy separate end markets, both benefit from the same macro tailwind: Western governments and corporations are re-shoring critical supply chains and willing to pay premium multiples for domestic manufacturing assets with regulatory clearances. Covenant's plan to produce 5,000 long-range missiles per year by full-scale operations at its Grand Prairie, Texas facility demonstrates the scale ambitions now standard in industrial platform builds .

Medical textiles manufacturers face similar volume expectations. A typical surgical drape supplier serving a national hospital network must maintain inventory buffers, pass FDA and ISO certifications, and guarantee just-in-time delivery schedules. These operational requirements create significant barriers to entry and justify the capital intensity that attracted three separate GP checks.

Fertility Services: A Continuation Play on Demographic Demand

Amulet Capital Partners' decision to pursue a continuation vehicle for US Fertility reflects a different but complementary logic. Continuation vehicles allow GPs to retain portfolio companies past the initial fund term, offering existing LPs liquidity while bringing in new capital to fund growth initiatives. The structure has gained traction in 2026 as sponsors seek alternatives to traditional sales processes in compressed valuation environments.

US Fertility operates a network of fertility clinics across multiple states, providing in-vitro fertilization (IVF), egg freezing, and related reproductive services. The company's appeal to Amulet lies in demographic fundamentals: women in developed economies are delaying childbearing into their mid-30s and beyond, driving demand for assisted reproductive technologies. Insurance coverage for fertility treatment has expanded materially since 2023, with major employers adding IVF benefits to compete for talent. This coverage shift transforms fertility services from a cash-pay luxury into a partially reimbursed medical necessity, stabilizing revenue and improving unit economics .

Our analysis: Amulet likely projects another 24 to 36 months of value creation before a strategic sale or secondary buyout. Fertility clinic operators trade on EBITDA multiples in the low double digits when they demonstrate network density, payor diversification, and physician retention. A continuation vehicle allows Amulet to execute de novo clinic openings, tuck-in acquisitions of independent practices, and payor contract renegotiations without the pressure of an imminent exit. The implication is that Amulet believes US Fertility's growth trajectory has not yet plateaued and that current public market comps undervalue the asset.

Healthcare Infrastructure vs. Clinical Risk: The Capital Allocation Divide

The distinction between these deals and traditional healthcare PE is critical. Montagu, Kohlberg, and Arlington are not buying hospitals, physician practices, or drug developers. They are buying suppliers to those entities. Medical textiles manufacturers and fertility service networks occupy a middle layer of the healthcare value chain: essential to clinical operations but insulated from direct reimbursement volatility and clinical liability.

This positioning matters for return profiles. A hospital system faces regulatory scrutiny, reimbursement cuts from Medicare Advantage plans, and malpractice exposure. A medical textiles supplier faces none of those risks. Its customers cannot switch vendors without re-validating supply chains, and its products are line items in hospital budgets, not profit centers subject to margin compression. The result is lower revenue growth but higher EBITDA margins and cash conversion, a profile that appeals to credit-oriented PE buyers in uncertain macro environments.

Fertility services sit slightly higher on the risk spectrum. US Fertility's revenue depends on patient volumes and payor mix, both of which can fluctuate with economic cycles and insurance policy changes. But the secular tailwind of delayed childbearing provides a demand floor that mitigates cyclical exposure. Our view: Amulet is effectively underwriting a demographic megatrend with a five-year lag, betting that the cohort of women now in their early 30s will convert into IVF patients by their late 30s, regardless of near-term GDP growth.

Fragmentation as Alpha: Lessons from Adjacent Sectors

The medical textiles consolidation thesis mirrors playbooks in adjacent industrial verticals. Alpine Investors recently made its first platform investment in the UK with the launch of Eight Group Service Partners, a hard facilities management platform, aiming to replicate its U.S. technical services success in a fragmented UK market . The parallel is instructive: both medical textiles and technical services are characterized by thousands of small, regional operators serving local customer bases. Both sectors suffer from underinvestment in technology, inconsistent service quality, and limited access to growth capital.

Alpine's UK entry signals that U.S. PE firms view European fragmentation as a replicable opportunity set. The same logic applies to medical textiles. Europe's healthcare supply chain remains less consolidated than the U.S., with family-owned textile manufacturers serving regional hospital networks. Montagu's participation in the sector likely reflects this geographic arbitrage, leveraging its European footprint to acquire and integrate suppliers ahead of U.S. competitors.

Kohlberg and Arlington's involvement suggests the U.S. market is not yet saturated. Despite decades of roll-up activity in healthcare distribution, medical textiles remain a subsector with pockets of fragmentation. The sponsors are betting they can achieve 15 to 20 percent EBITDA growth annually through a combination of organic volume increases, cross-selling, and margin expansion from shared services. If executed, that trajectory supports hold periods of four to six years and gross IRRs in the mid-20s, acceptable returns in an environment where mega-buyouts struggle to clear 15 percent.

Capital Intensity Meets Regulatory Moats: A Durable Combination

The capital intensity of medical textiles manufacturing creates a natural competitive moat. Building a new production facility with FDA-compliant cleanrooms, sterilization equipment, and quality control systems requires tens of millions of dollars in upfront investment. Scaling to meet national demand requires additional facilities or significant capacity expansions. These economics favor incumbents and deter new entrants, particularly in a rising interest rate environment where project finance costs have doubled since 2021.

The regulatory dimension reinforces the moat. Medical textiles manufacturers must pass FDA 510(k) clearances or CE marking in Europe, maintain ISO 13485 certifications for quality management, and comply with stringent traceability and recall protocols. These requirements are not onerous for established operators but represent significant friction for startups. The result is a market structure where incumbents enjoy pricing power and customer lock-in, two attributes PE buyers prize.

This dynamic is not unique to healthcare. Covenant's defense manufacturing model relies on similar barriers: the company secured an Other Transaction Agreement with the U.S. Army for accelerated testing and qualification of its Anthem missile system, and a contract with the U.S. Navy's Rapid Capabilities Office valued at roughly $70 million to adapt the system into a Maritime Anthem variant . These government contracts validate Covenant's technology and manufacturing capabilities, creating a competitive advantage that rivals cannot replicate without years of R&D and testing. The Pentagon is also revising its purchasing terms to encourage contractors to add manufacturing capacity, a tailwind that benefits Covenant's plan to produce 1,000 Anthem units per year starting Q1 2027, scaling to 5,000 units annually at full capacity .

Medical textiles suppliers operate under similar dynamics. Once a hospital system qualifies a vendor and integrates its products into surgical protocols, switching costs are high. The vendor relationship becomes annuity-like, generating predictable cash flows that underpin leveraged buyout structures. For sponsors deploying capital in 2026, this predictability is a scarce commodity.

The Plocamium View

The convergence of three separate GP checks on medical textiles and a continuation vehicle on fertility services reveals an institutional consensus: healthcare infrastructure assets with regulatory moats and inelastic demand are the scarcest risk-adjusted return opportunities in the current cycle. These are not growth equity moonshots or distressed turnarounds. They are compounders, businesses that generate mid-teens EBITDA growth, convert 80 percent of EBITDA to free cash flow, and delever naturally over a five-year hold.

Our thesis is that these deals represent the leading edge of a broader shift in PE deployment. As software multiples compress, consumer discretionary weakens, and financial services face regulatory headwinds, industrial healthcare infrastructure emerges as the consensus safe haven. The sector combines defensive revenue profiles, fragmentation-driven M&A pipelines, and secular tailwinds that are multi-decade in duration.

What Plocamium sees that the market may be underestimating: the interplay between re-shoring and healthcare capacity expansion. Western governments are subsidizing domestic manufacturing across defense, semiconductors, and critical healthcare supplies. Medical textiles qualify as critical supplies under pandemic preparedness frameworks, positioning incumbent manufacturers to capture government contracts and grants in addition to commercial revenue. This dual-revenue model, commercial plus government, could expand EBITDA margins by 200 to 300 basis points over the next three years, a boost that is not yet reflected in transaction multiples.

The second-order play is vertical integration. As medical textiles consolidators scale, they gain leverage over upstream raw material suppliers and downstream hospital group purchasing organizations. That leverage translates into pricing power. In a sector where cost-of-goods-sold is 40 to 50 percent of revenue, a 200-basis-point improvement in gross margin flows directly to EBITDA. Sponsors who build platforms now, at eight to ten times EBITDA, can exit in 2029 or 2030 at ten to twelve times, purely on multiple expansion driven by scale and margin profile, before accounting for organic growth.

Fertility services offer a different but equally compelling angle. Amulet's continuation vehicle bet is a wager that U.S. fertility treatment penetration still lags European levels by five to seven percentage points. As insurance coverage expands and social acceptance increases, that gap closes. If US Fertility captures even a fraction of that incremental demand, the business grows revenue at 12 to 15 percent annually without market share gains. Layering in tuck-in acquisitions and geographic expansion, the company could sustain 20 percent top-line growth through 2028, supporting a valuation re-rating that justifies the continuation vehicle structure.

The risk, of course, is execution. Medical textiles roll-ups require operational discipline: integrating manufacturing facilities, harmonizing quality systems, and retaining key customer relationships through ownership transitions. Fertility clinic networks require physician retention and payor contract management. But these are known risks, manageable through hands-on portfolio company support and experienced operating partners. The unknowable risks, such as reimbursement cliffs or disruptive technologies, are largely absent from these models. That asymmetry is what makes the opportunity compelling.

So What: Follow the Capital Into Fragmented Essentials

The actionable takeaway for institutional allocators is straightforward: the next wave of PE outperformance will come from fragmented, capital-intensive, regulation-protected essential services and supplies. These are not the sectors that generate headlines or command venture-scale valuations. They are the plumbing of the economy, the businesses that generate steady cash flows regardless of whether GDP grows at one percent or three percent.

Medical textiles and fertility services exemplify this archetype. Both sectors benefit from inelastic demand, both are undergoing consolidation, and both offer multiple paths to value creation beyond revenue growth. As the broader PE market grapples with valuation discipline and uncertain exit markets, these businesses provide a rare combination: downside protection through essential demand and upside optionality through fragmentation and margin expansion.

Montagu, Kohlberg, Arlington, and Amulet have placed their bets. The question for other institutional players is whether they recognize the pattern before the entry multiples re-rate. If 2026 is the year healthcare infrastructure consolidation accelerates, 2027 will be the year transaction multiples reflect that consensus. The window to deploy at attractive valuations is narrowing.